Honour For CEO Of Inovio Pharmaceuticals Inc. (NYSEMKT:INO)
On November 14, 2013 Inovio Pharmaceuticals Inc. (NYSEMKT:INO) announced that its President and Chief Executive Officer, Dr. J. Joseph Kim has been selected for the 2013 Achievement in Drug Discovery and
Development Award from the KASBP (Korean American Society in Biotech and Pharmaceuticals).
KASBP is a non-profit organization that seeks to promote drug discovery and development through recognitions in the community, collaborations and information exchanges between the U.S. and Korean pharmaceutical companies as well as research centers.
The award recognizes Dr. Kim as one of the prominent scientist in moving the development in the field of DNA vaccines. The award has been sponsored by the leading Korean pharmaceutical company, Daewoong Pharmaceuticals Inc.
Dr. Kim originally founded VGX Pharmaceuticals that through acquisition became Inovio Pharmaceuticals Inc. (NYSEMKT:INO) and is one of the leading biotechnology company engaged in the advancement of DNA vaccines toward commercialization in collaboration with Roche, Merck & Co., Inc. (NYSE:MRK) and National Institute of Health among others.
Inc. (NYSEMKT:INO) is engaged in creating the vaccines of tomorrow targeted at prevention and treatment of cancers
and challenging infectious diseases.
KASBP President, Jae-Hun Kim, Ph.D. who is currently been associated with Merck & Co., Inc. (NYSE:MRK) Research Laboratories expressed his happiness to present the award to Dr. Joseph Kim for his significant achievement for invention and development in the field as a scientist as well as a businessman.
While in response to his selection, Dr. J. Joseph Kim of Inovio Pharmaceuticals Inc. (NYSEMKT:INO) said, “I thank KASBP for this award and for their tireless
work in building a bridge between the U.S. and Korea with a goal to advance drug discovery and development.”
Dr. Kim also expressed that this honor recognizes the work of countless scientists who have pursued the potential of DNA vaccines and affirmed that at Inovio, the company has shown clinical results which are believed to change the medical practice in treating HIV, cancer, malaria and other infectious diseases.